Scarica l'app Stockscreener
3.37
0.30%
-0.010
Dopo l'orario di chiusura:
3.47
0.10
+2.97%
Precedente Chiudi:
$3.38
Aprire:
$3.4
Volume 24 ore:
1.47M
Relative Volume:
0.35
Capitalizzazione di mercato:
$549.51M
Reddito:
$400.57M
Utile/perdita netta:
$9.21M
Rapporto P/E:
84.25
EPS:
0.04
Flusso di cassa netto:
$146.36M
1 W Prestazione:
-3.71%
1M Prestazione:
-25.11%
6M Prestazione:
+157.25%
1 anno Prestazione:
+123.18%
Intervallo 1D:
$3.34
$3.5075
Intervallo di 1 settimana:
$3.31
$3.925
Portata 52W:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.37 | 549.51M | 400.57M | 9.21M | 146.36M | 0.04 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.18B | 1.33B | 1.04B | 27.90 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Downgrade | Jefferies | Buy → Hold |
| 2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant - Stock Titan
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - Yahoo Finance
Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing - Minichart
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity - Investing.com
Ironwood Pharma Maintains Revolving Credit Facility to 2028 - TipRanks
Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10 - TradingView
Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028 - Stock Titan
Investment Review: Can Ironwood Pharmaceuticals Inc stock double in the next yearJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Aug Reactions: Will Ironwood Pharmaceuticals Inc outperform the market in YEAR2025 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? - Yahoo Finance
Ironwood Pharma Stock Quote, Share Price, News and Analysis - Longbridge
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - itemonline.com
US Stocks Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSJuly 2025 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Report: Can Ironwood Pharmaceuticals Inc stock double in the next yearPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
IRWD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IRWD Should I Buy - Intellectia AI
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 10.1%Time to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Plays Key Role In Nasdaq Futures Healthcare - Kalkine Media
Jefferies Maintains Hold on Ironwood Pharmaceuticals (IRWD) Feb 26, 2026 - Meyka
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha
Jefferies raises Ironwood Pharmaceuticals stock price target on Linzess outlook - Investing.com Canada
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Finviz
IRWD: Analyst Raises Price Target and Maintains Rating | IRWD St - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9.5% on Analyst Upgrade - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $10.00 at Citizens Jmp - MarketBeat
GSA Capital Partners LLP Has $405,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue - simplywall.st
Ironwood (IRWD) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ironwood Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Ironwood Pharmaceuticals Balances Growth Plans With Pricing Risks - TipRanks
Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highli - GuruFocus
Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding - Stock Titan
Tax-withholding share sale by Ironwood (IRWD) Chief Commercial Officer - Stock Titan
Ironwood Pharmaceuticals (IRWD) officer sells shares to cover tax withholding - Stock Titan
Ironwood Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Ironwood Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-02-25 - Seeking Alpha
Ironwood Pharmaceuticals Faces Tumultuous Week Amid Market Volatility - StocksToTrade
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownWhat's Next? - MarketBeat
Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ironwood Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop - Investing.com Australia
Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop By Investing.com - Investing.com South Africa
IRWD: 2026 guidance targets >$1.1B LINZESS sales and pivotal apraglutide Phase III launch - TradingView
Form 8K Ironwood Pharmaceuticals Inc For: 25 February By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals (IRWD) Targets Over $300M Adjusted EBIT - GuruFocus
Ironwood (IRWD) Reports Q4 Revenue Below Expectations - GuruFocus
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):